



ABN 53 075 582 740

ASX ANNOUNCEMENT

15 June 2017

Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data

- **Hosted by US Army Medical Research and Materiel Command in West Virginia**

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system, will present a poster at the post-traumatic stress disorder (PTSD) State of the Science Summit.

The Summit entitled “Pathophysiology of PTSD: Rethinking Drug Targets” is an invitation-only summit hosted by US Army Medical Research and Materiel Command this week in West Virginia. Bionomics is one of the subject matter experts selected to participate by the committee of PTSD drug treatment stakeholders.

Patients with PTSD display multiple symptoms in the clusters of intrusion, avoidance, arousal and reactivity and negative alterations of cognition and mood. The treatment of PTSD is both complex and challenging because current medications, such as selective serotonin reuptake inhibitors and benzodiazepines, have limited effects in patients and have multiple side effect issues.

At this conference Bionomics presented a poster highlighting the potential of BNC210 as a drug therapy for PTSD, through the results of a Phase 2 clinical trial in patients with Generalized Anxiety Disorder (GAD), a Phase 1 clinical trial evaluating the effects of BNC210 on panic attacks induced in healthy volunteers and in preclinical models, including models of fear extinction and depression.

In neuroimaging studies in GAD and in PTSD patients, the emotional faces task activates the amygdala. In anxiety, connections between the anterior cingulate cortex and the amygdala are strengthened. In a Phase 2 clinical trial in GAD patients, BNC210 significantly reduced both amygdala activation induced by viewing fearful faces and the resting state connectivity between the left amygdala and the anterior cingulate cortex.

Patients suffering from PTSD also demonstrate deficits in fear extinction which has been proposed as an explanation for intrusive thoughts and why sufferers continue to re-experience the traumatic event. BNC210 has demonstrated efficacy in the contextual fear-conditioning extinction paradigm in C56BL6 mice where it significantly enhanced fear extinction, reducing fear behaviour, while diazepam (Valium) demonstrated an inhibitory effect resulting in prolonged fear behaviour.

In humans, BNC210 treatment reduced the emotional impact of a CCK-4 induced panic attack. Individuals who suffered an induced panic attack, and to whom BNC210 was administered, showed faster recovery following their unpleasant physical and emotional experience, compared to placebo.

The data shown in this poster presentation continues to demonstrate BNC210 is a potent anxiolytic compound with equivalent acute efficacy to benzodiazepines with anti-depressant properties and few side effects.

A copy of the poster presentation is available on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

US

Stern Investor Relations
Beth DelGiacco
+1 212 362 1200
beth@sternir.com

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

About the Post-traumatic Stress Disorder (PTSD) State of the Science Summit (SoSS)

The Summit, which takes place June 13 and 14 brings together experts from government, academia, and industry. The format of the summit will include scientific presentations and small working groups meeting to discuss responses to key questions. At the end of the Summit, participants will reconvene to hear and discuss the working group findings. By collaborating together intensively over two days, participants will have the opportunity to exchange ideas, problem-solve and initiate viable partnerships for future efforts for finding effective treatments for PTSD.

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC105 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.